In fact, a study performed in an animal model of stroke showed that the treatment with anti-VEGF reduced the incidence of HT along with attenuated degradation of BBB components and MMP-9 activation even in the presence of tPA treatment (263), suggesting that the modulation of neoangiogenic factors could be an interesting strategy to avoid or lessen HT. The gene discussed is VEGFA; the disease is stroke disorder.